Jianxiang Wang
Chinese Academy of Medical Sciences · Institute of Institute of Hematology & Blood Diseases Hospital · The Haematology Hospital of the Chinese Academy of Medical Sciences
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jianxiang Wang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:42 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07925190 · A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) PatientsBeijing InnoCare Pharma Tech Co., Ltd. · not yet recruiting · Acute Myeloblastic Leukaemia · principal investigator
- Ph2NCT07743112 · A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid LeukemiaMaxinovel Pty., Ltd. · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1NCT07347171 · A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological MalignanciesCullgen (Shanghai),Inc · recruiting · Leukemia, AML, MDS · principal investigator
- Ph1NCT07169487 · Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I StudyInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Cytokine Release Syndrome, ICANS · principal investigator
- Ph1/Ph2NCT07153068 · SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic MalignanciesInstitute of Hematology & Blood Diseases Hospital, China · recruiting · T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML) · principal investigator
- Ph1NCT07137637 · HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid LeukemiaHangzhou Polymed Biopharmaceuticals, Inc. · recruiting · Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) · principal investigator
- Ph1NCT07109518 · uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic MalignanciesInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma · principal investigator
- N/ANCT06481228 · Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult · principal investigator
- N/ANCT06481241 · Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALLInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult · principal investigator
- N/ANCT06461351 · Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel InjectionJuventas Cell Therapy Ltd. · recruiting · B-cell Tumors · principal investigator
- N/ANCT06450067 · Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic LeukemiaJuventas Cell Therapy Ltd. · recruiting · B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph3NCT06389292 · A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaAscentage Pharma Group Inc. · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT06387121 · Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Precursor Cell Lymphoblastic Leukemia-Lymphoma · principal investigator
- Ph1NCT06387082 · A Clinical Study of HMPL-506 in Patients With Hematological MalignanciesHutchmed · recruiting · Hematological Malignancies · principal investigator
- N/ANCT06386302 · Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · AML, Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT06206174 · TGRX-814 Chinese Phase I/II in Patients With Hematological MalignanciesShenzhen TargetRx Co., Ltd. · recruiting · Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT06009107 · A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)Juventas Cell Therapy Ltd. · withdrawn · B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT05924750 · A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) · principal investigator
- N/ANCT05801835 · A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for InjectionCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · unknown · Acute Myeloid Leukemia · principal investigator
- N/ANCT05739409 · LILRB4 STAR-T Cell Therapy for Monocytic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia · principal investigator
- Ph2NCT05660473 · Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Precursor Cell Lymphoblastic Leukemia-Lymphoma · principal investigator
- Ph2NCT05594784 · Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLInstitute of Hematology & Blood Diseases Hospital, China · completed · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · principal investigator
- Ph1/Ph2NCT05579132 · A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)MSD R&D (China) Co., Ltd. · recruiting · Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT05320809 · Study of 3D189 in Patients With Hematologic Malignancies3D Medicines · completed · Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma · principal investigator
- Ph3NCT05054543 · Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AMLApollomics Inc. · terminated · Relapsed/Refractory AML · principal investigator
- Ph1NCT04839341 · Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML PatientsApollomics Inc. · completed · Relapsed/Refractory AML · principal investigator
- Ph2NCT04684147 · Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic LeukemiaJuventas Cell Therapy Ltd. · recruiting · Relapsed or Refractory Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT04606433 · Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaSichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT04402723 · Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AMLSuzhou Zelgen Biopharmaceuticals Co.,Ltd · terminated · Acute Myeloid Leukemia (AML) · principal investigator
- Ph1NCT04275518 · A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.Ascentage Pharma Group Inc. · unknown · Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) · principal investigator
- Ph1NCT04230473 · A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic LeukemiaJuventas Cell Therapy Ltd. · completed · Relapsed or Refractory Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT03913949 · A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesAscentage Pharma Group Inc. · active not recruiting · Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma · principal investigator
- Ph1NCT03560908 · Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 MutationInstitute of Hematology & Blood Diseases Hospital, China · withdrawn · Relapsed AML, T(8;21), C-KIT Mutation · principal investigator
- Ph1NCT03483948 · Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid LeukemiaHutchison Medipharma Limited · terminated · Acute Myeloid Leukemia · principal investigator
- Ph1NCT03125876 · A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)Sunshine Lake Pharma Co., Ltd. · terminated · Acute Myeloid Leukemia (AML) · study chair
- Ph1/Ph2NCT03031262 · Efficacy and Safety of Chidamide in CBF LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · active not recruiting · AML · principal investigator
- Ph1/Ph2NCT03031249 · Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · enrolling by invitation · AML · principal investigator
- Ph1/Ph2NCT03021395 · Efficacy of Decitabine in Clearance of MRDInstitute of Hematology & Blood Diseases Hospital, China · withdrawn · AML · principal investigator
- Ph3NCT03021330 · Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AMLInstitute of Hematology & Blood Diseases Hospital, China · active not recruiting · AML · principal investigator
- Ph1NCT02975687 · CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukaemia Recurrent · principal investigator
- Ph2NCT02937662 · Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AMLInstitute of Hematology & Blood Diseases Hospital, China · completed · Acute Myeloid Leukemia · principal investigator
- Ph2NCT02523976 · Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Acute,Leukemia, Lymphoid · principal investigator
- N/ANCT02432872 · Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 YearsJianxiang Wang · unknown · Acute Myeloid Leukemia · principal investigator
- Ph4NCT02267993 · Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML PatientsInstitute of Hematology & Blood Diseases Hospital, China · completed · Thrombocytopenia · principal investigator
- Ph3NCT01633099 · Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia PatientsJianxiang Wang · unknown · Untreated Adult Acute Myeloid Leukemia, Effect of Drugs, Drug Safety · principal investigator
- Ph2NCT01503502 · A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaJiangsu HengRui Medicine Co., Ltd. · unknown · Myelogenous Leukemia, Chronic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in childhood acute lymphoblastic leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 12:42 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- 124 citationsRCR 3.0
- 107 citationsRCR 7.6
- MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.Blood · 201598 citationsRCR 2.6
- Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.J Hematol Oncol · 202081 citationsRCR 2.9
- Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia.Leukemia · 201074 citationsRCR 1.8
- Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.J Biol Chem · 201453 citationsRCR 1.4
- Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.Br J Haematol · 202052 citationsRCR 2.0
- Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes.Biol Blood Marrow Transplant · 201424 citationsRCR 0.9
- Treatment of Testicular Relapse of B-cell Acute Lymphoblastic Leukemia With CD19-specific Chimeric Antigen Receptor T Cells.Clin Lymphoma Myeloma Leuk · 202024 citationsRCR 0.9
- Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation.Pediatr Blood Cancer · 201720 citationsRCR 0.6